Sanofi S.A. / Boehringer Ingelheim GmbH (consumer healthcare business swap)

Animal Health and Consumer Healthcare (Business Swap)

$13.5B Merial enterprise value (EUR 11.4B / ~$13.53B)

Disease Overview

The transaction was a two-sided business swap, not a single-disease acquisition: Boehringer Ingelheim took Sanofi's Merial animal health business (companion animal and livestock vaccines, parasiticides such as Frontline and NexGard) while Sanofi took BI's consumer healthcare (OTC) business plus EUR 4.7B cash. Both sides traded out of secondary segments to double down on category leadership.

Competitive Landscape

The June 27, 2016 Sanofi-Boehringer Ingelheim swap (EUR 22.8B / ~$25.1B; closed January 1, 2017 in most markets) repositioned both companies into category leadership rather than diversification. On the animal health side, BI absorbed Merial (EV EUR 11.4B / ~$13.5B per FTC documentation, https://www.ftc.gov/news-events/news/press-releases/2016/12/ftc-requires-divestitures-condition-proposed-1353-billion-deal-between-german-pharmaceutical) to roughly double its animal health revenue to ~EUR 3.8B and become the global #2 behind Zoetis, ahead of Merck Animal Health, Elanco, and Bayer Animal Health. On the consumer healthcare side, Sanofi added BI's OTC franchise (EV EUR 6.7B / ~$8B) to scale into a global top-three consumer health player against Bayer, J&J/Kenvue, GSK (later Haleon), and Reckitt — reaching combined sales of ~EUR 4.9B. The FTC required limited divestitures to clear U.S. antitrust. Strategic reception was broadly positive: both companies exited subscale franchises and gained scale in core categories without leveraging up — a model later cited when J&J spun Kenvue and GSK spun Haleon. Bloomberg and FiercePharma framed the swap as the cleanest way for diversified pharmas to refocus on Rx innovation.